Related Experiment Videos
A controlled trial of tick-borne encephalitis vaccination in patients with multiple sclerosis
Ulf Baumhackl1, Claudia Franta, Johann Retzl
1Department of Neurology, General Hospital, A-3100 St Pölten, Austria. neurologie@kh-st-poelten.at
Abstract:
The aim of this study was to investigate a possible link between a single vaccination against tick-borne encephalitis (TBE) and the appearance of one or more new cerebral lesions in magnetic resonance imaging (MRI) and/or a clinical relapse of MS. Fifteen MS patients with documented history of MS relapses living in a TBE endemic area were matched with 15 patients selected from a patient database containing 500 cases of MS. Three patients in each group were unvaccinated while all others had basic immunisation and regular booster vaccinations. Patients of the vaccination group received a single dose (3.3 microg) of a TBE vaccine. TBE antibodies were detected by ELISA and confirmed by neutralisation test. MRI was used as marker for disease activity and progression in addition to the clinical neurological examination. No association was seen between TBE vaccination and MRI detected disease activity, clinical relapse or disease progression of MS.
Insights
A single tick-borne encephalitis (TBE) vaccine did not trigger new brain lesions or relapses in multiple sclerosis (MS) patients. This study found no link between TBE vaccination and MS disease activity or progression.
Area of Science:
- Neuroimmunology
- Vaccinology
- Infectious Disease Epidemiology
Background:
- Multiple Sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system.
- Tick-borne encephalitis (TBE) is a viral infection prevalent in endemic areas, posing a potential concern for individuals with pre-existing neurological conditions.
- The safety of vaccinations in MS patients is a critical consideration for disease management.
Purpose of the Study:
- To investigate the potential association between a single TBE vaccination and the emergence of new cerebral lesions on MRI.
- To determine if TBE vaccination correlates with clinical relapses or disease progression in MS patients.
- To assess the immunological response to TBE vaccination in MS patients.
Main Methods:
- A case-control study matching 15 MS patients with TBE vaccination history to 15 unvaccinated MS patients from a larger cohort.
- Utilizing Magnetic Resonance Imaging (MRI) to monitor for new cerebral lesions as a marker of disease activity.
- Conducting clinical neurological examinations to assess for MS relapses and disease progression.
- Employing ELISA and neutralization tests to confirm TBE antibody detection post-vaccination.
Main Results:
- No significant association was observed between TBE vaccination and the appearance of new cerebral lesions on MRI.
- TBE vaccination did not correlate with an increased rate of clinical relapses in MS patients.
- No evidence of accelerated disease progression was detected in vaccinated MS patients compared to unvaccinated controls.
Conclusions:
- A single dose of TBE vaccine does not appear to exacerbate disease activity or progression in patients with multiple sclerosis.
- The findings suggest that TBE vaccination is likely safe for MS patients living in endemic areas.
- Further research could explore the long-term effects of booster vaccinations on MS activity.